Add like
Add dislike
Add to saved papers

Ototoxicity of cis-diamminedichloroplatinum.

In 19 evaluable cancer patients treated with cis-diamminedichloroplatinum (cis-DDP) Platidiam-Lachema containing chemotherapy the ototoxicity was assessed. There was an increase of hearing threshold of air-conduction in frequency of 6000 and 8000 Hz as compared with pretreatment audiograms in four patients (21%). In one case only the hearing loss was reversible. The usual hearing loss was of 10--15 dB and maximal of 20 dB. In those four patients with ototoxicity the decrease of creatinine clearence under 60 ml/min occurred at the same time. It is suggested that the altered renal function could be a cause of cis-DDP level rise in body liquids and in this way a cause of further more severe side effects. Neither subjective hearing loss nor tinnitus nor otalgia was found. The cis-DDP caused high frequency hearing loss but has not affected the correct speech percept. To avoid serious cis-DDP ototoxicity it is necessary to monitor renal functions and audiograms carefully and to administer cis-DDP slowly in chloride-containing vehicles after sufficient prehydratation.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app